This page is dedicated to research that has been undertaken in to PROS:

Here is a website that gives you a detailed explanation of PROS:

The following research papers are collated in date order, for the latest research please scroll down the page:


Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome (FULL ARTICLE) 

Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA (ABSTRACT ONLY)


PIK3CA-Related Overgrowth Spectrum (PROS): Diagnostic and Testing Eligibility Criteria, Differential Diagnosis, and Evaluation (FULL ARTICLE)

Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrum (FULL ARTICLE)


Heterozygous expression of the oncogenic Pik3caH1047R mutation during murine development results in fatal embryonic and extraembryonic defects (FULL ARTICLE)

Mouse models of human PIK3CA-related brain overgrowth have 1 acutely treatable epilepsy (FULL ARTICLE)


Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans (ABSTRACT ONLY)

Cancer drug could treat blood vessel deformities (FULL ARTICLE)

Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation (FULL ARTICLE)

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution (FULL ARTICLE)


Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing (FULL ARTICLE)

Mosaic Disorders and the Taxonomy of Human Disease (FULL ARTICLE)

Gene Editing With CRISPR-Cas9: The Next Step In Human Evolution Will Be Worth $25 Billion By 2030 (FULL ARTICLE)


Gene edited human stem cells provide insights into early human development and complex growth disorder.


In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS) (FULL ARTICLE)

Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome (FULL ARTICLE)

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations (FULL ARTICLE)

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum (FULL ARTICLE)

Cancer-AssociatedPIK3CAMutationsinOvergrowthDisorders (FULL ARTICLE)

Severe PI3Kinase Overgrowth Syndrome Treated with the AKT Inhibitor Miransertib


Update on UK PIK3CA Overgrowth Research

Update on PIK3CA Research_Patients_Oct_2018                     


Open-Label, Phase 1/2 Study of Miransertib (ARQ 092), an Oral pan-AKT Inhibitor, in Patients with PIK3CA-Related Overgrowth Spectrum (PROS): Preliminary Result. (FULL ARTICLE)

Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome (ABSTRACT ONLY)

Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner (FULL ARTICLE)

ArQule’s Approach to Rare Overgrowth Diseases: Miransertib, a Portfolio in a ProductPursuing Treatments for Biomarker-Driven Cancers and Rare Diseases (Page 17 onwards for PROS)

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Report by Dr. R Madson from PI3K/PTEN pathway scientific meeting, July 2019